These key personnel additions will ensure that we continue to offer top clinical data analyses and will enable us to take a more proactive and quantitative approach for our clients and partners.
Boston, MA (PRWEB) May 29, 2012
Clintara, a privately held and funded company that works with leading pharmaceutical companies and clinical research organizations to optimize outcomes of Central Nervous System (CNS) clinical studies, today announced that both Dr. Cara Pendergrass and Philip Rauh have joined the company as Vice Presidents.
“Dr. Pendergrass will utilize her clinical and industry experience to enhance our internal clinical expertise and to leverage key clinical relationships with individual thought leaders specific to indications and institutional partners, like Massachusetts General Hospital, Keio Hospital in Tokyo, Cedars Sinai, Universidad Favaloro in Buenos Aires, and Klinikum der Universität München in Munich” said Clintara President, Colin Bower. “Cara will ensure that we effectively integrate these clinical assets with our new platform to continue to offer top clinical data analyses - mid study and real time - through an integrated and automated surveillance system designed to optimize clinical study results.”
Dr. Pendergrass will manage a clinical team which includes more than 35 prominent CNS clinicians in the Americas, MENA and APAC regions, offering expertise across indications, countries, sites, languages and scales.
Mr. Rauh will focus on implementing the delivery of the Clintara platform to clients (including data collection, analysis and reporting) in a simple, effective and timely manner.
“Philip’s extensive analytical experience with top-tier institutions in the financial services industry enhances our ability to collect, analyze and report on key data, in study,” said Bower. “His experience delivering long-term value for clients in a highly regulated industry will enable us to take a more proactive and quantitative approach to data collection, analyses and overall platform delivery for our clients and partners.”
Clintara also announced Celine Houser has been promoted to Executive Director, Program Development, working with clients on program design and the initial phase of program implementation. Clintara recently expanded its operational and technical staff, and continues to offer attractive opportunities to qualified personnel. (See http://www.clintara.com and click on About Us).
Please contact Colin Bower for further information at cbower(at)clintara(dot)com.
The Clintara team (utilizing site-friendly surveillance techniques and site-independent reviews) provides clinical studies with the best opportunity to demonstrate placebo separation, maintain a high level of inter-rater reliability, enhance subject selection validity and optimize trial outcomes.
The Clintara team is led by industry pioneer Steven D. Targum, M.D., Scientific Director, who continues to develop innovative practices and technology to improve ratings methodologies and optimize clinical trial outcomes. Clintara recently rolled out its new technology platform which collects data from sites and other sources in any format, including manual faxing, audio mp3, smartpens, mobile devices and tablets across operating systems. Clintara’s platform is ‘collection neutral’ so that Clintara can focus on ease of use, speed, data integrity, and automated real time reporting and analytics. In this way, Clintara can continue to customize programs to meet the exact sponsor, CRO, site and protocol needs and requirements.
Since 2009, Clintara has conducted over 25 studies, which have spanned 489+ sites across 15+ countries. We have provided study design, subject validation, rater training and certification and ratings diligence services worldwide, including North America, South America, Eastern Europe, Western Europe, and Asia Pacific. Our studies have consisted of small phase Ib studies, phase II and IIb studies, as well as large global phase III trials. Our clients are high growth companies, biotech companies, mid-sized pharma, and top 20 biopharmaceutical companies.
Along with consultants from top tier academic research centers, multilingual mental health professionals, technologists, and clinical support staff, the Clintara team has decades of experience in all aspects of designing and implementing training and QA programs for global clinical trials. (To learn more about our team, go to http://www.clintara.com and click on About Us.)
Our expertise spans the spectrum of neuroscience, including psychiatry and neurology, and includes formal partnerships with the following institutions in North and South America, Europe and Asia, including:
- Favaloro University (Universidad Favaloro)
- Keio University
- Ludwig Maximilian University of Munich (Ludwig-Maximilians-Universität München)
- Massachusetts General Hospital
About Dr. Cara Pendergrass
Dr. Pendergrass has extensive experience in developing and executing comprehensive clinical studies involving various psychiatric populations, including schizophrenia, bipolar disorder, depression and dementia in addition to specialty training in clinical neuropsychology and neuroimaging.
As a fellow at Dartmouth Medical School, Dr. Pendergrass contributed to the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a multisite longitudinal clinical/imaging/genetic biomarker study with the goals of defining the progression of Alzheimer’s Disease, identification of biomarkers, and the discovery and development of treatments. Dr. Pendergrass also maintains her clinical license as a psychologist with a specialty in Neuropsychology. She is scheduled to complete her Board Certification in Clinical Neuropsychology in late 2012.
Dr. Pendergrass graduated with a B.A. in Psychology with Honors from Vanderbilt University and obtained an M.S. and Ph.D. in Clinical Psychology with a specialization in Neuropsychology from Rosalind Franklin University of Medicine and Science. She completed her internship and post-doctoral fellowship in Clinical Neuropsychology at the University of Illinois-Chicago and Dartmouth Medical School, respectively.
About Philip Rauh, MA
Philip Rauh holds a MA of International Economics with emphasis on quantitative analysis from the Graduate Institute of International Studies of the University of Geneva in Switzerland. He has spent most of his career in the financial service industry and has worked in various European countries as well as the US and Canada. He held various leading roles in the areas of data analysis, client management and process implementation. Philip recently joined Clintara from a Boston based private equity boutique where he was responsible for global client and sales management and was a member of the executive leadership team. At Clintara, Philip oversees client services with a focus on product and service delivery and quality control.